NB: As of October 2025, Excidium newsletters are no longer maintained and deep dives are not public due to ongoing client commitments.
BUY
Milestone Pharmaceuticals aims to treat Paroxysmal Supraventricular Tachycardia (PSVT) with their lead asset etripamil - an intranasally administered calcium channel blocker. After a recent CRL due to CMC concerns, Milestone submitted a response and has been assigned a new PDUFA action date in December 2025.
18 July 2025
Anavex Life Sciences is targeting Alzheimer’s Disease (AD) with their lead asset blarcamesine, an orally administered activator of the sigma-1 receptor. The company is currently awaiting the decision of the EMA, due in the first half of 2025. We express concerns regarding high drop out rates and apparent trial result obfuscation.
9 Jan 2025
BUY
Abeona Therapeutics is targeting Recessive dystrophic epidermolysis bullosa with their pz-cel gene therapy. Abeona remains undervalued heading into a promising launch in RDEB after receiving in April 2025.
last update: 05 June 2025
SELLAS Life Sciences is targeting acute myeloid leukemia (AML) with their lead asset galinpepimut-s, a Wilm’s Tumour 1 (WT1) peptide vaccine. The next catalyst is the conclusion and readout of a Phase 3 trial.
last update: 26 Jan 2025
April 2025
INmune Bio is developing XPro1595, a TNF inhibitor for Alzheimer’s Disease. In June they presented results of a Phase 2 study which failed to meet its primary endpoint, confirming our prior opinion of the efficacy of XPro.
June 2025
Arcutis Biotherapeutics' ZORYVE targets Mild-Moderate atopic dermatitis. Operational challenges could pose a problem for the drug's tough commercialisation roadmap.
Arcutis (ARQT)
June 2025
After receiving approval for ROS1+ NSCLC, NUVB stock dropped. We break down the cause and mechanics of this move caused by post marketing requirements.